Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trialBerend J. van der Wilk, Stijn van Esser, W. Edward Fiets et al.|The Lancet Oncology|2025Cited by 95
LBA75 Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): A phase-III stepped-wedge cluster randomised trialBerend J. van der Wilk, JJB van Lanschot, Ben M. Eyck et al.|Annals of Oncology|2023Cited by 51
Surveillance of Clinically Complete Responders Using Serial <sup>18</sup>F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant ChemoradiotherapyMaria J. Valkema, Roelf Valkema, Berend J. van der Wilk et al.|Journal of Nuclear Medicine|2020Cited by 15
Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommonMaria J. Valkema, J. Jan B. van Lanschot, Manon C.W. Spaander et al.|British journal of surgery|2023Cited by 8
The effectiveness of neoadjuvant chemoradiotherapy in oesophageal adenocarcinoma with presence of extracellular mucin, signet‐ring cells, and/or poorly cohesive cellsMaria J. Valkema, Michail Doukas, Anne‐Marie Vos et al.|The Journal of Pathology Clinical Research|2023Cited by 2